



OFF-LABEL USE OF OMALIZUMAB IN REFRACTORY CASES TO APPROVED THERAPIES

C. Medarde, C.L. Dávila Fajardo, C. Fernández Lopez, S. Belda Rustarazo, S. Ruiz Fuentes, C. García Fernández, C. Gomez Peña, A.M. Valle Díaz de la Guardia, C. Ruiz Cruz, J. Cabeza Barrera.
Hospital San Cecilio, Granada, Spain

OBJECTIVES

To evaluate the use of Omalizumab beyond its approved indications and to discuss the results of the therapy in two off-label uses resistant to approved therapies.

Omalizumab is an antibody used for the treatment of asthma running with high in-blood levels of IgE (>76UI/ml).


METHODS

Revision of medical charts and bibliographic in order to process the off-label approval. Clinical evolution was followed from the first administration of the antibody to present.

Cases presented:

- The first case was an out of control ***asthma secondary to Churg-Strauss vasculitis***, with normal IgE levels and no allergic component.
- The second was a case of ***persistant atopic dermatitis with high levels of IgE*** (800-900 UI/mL) and adverse effects to all therapeutic options tried.

Use of Omalizumab:
150 mg every 4 weeks.
450 mg every 15 days.



RESULTS

After 4 doses, vasculitis shows no activity, although asthma recurrent crisis continue, even though they do not cause emergency episodes.

In the second case, the patient has a satisfactory clinical evolution after a year treatment with remission of the symptoms and normal serum levels of IgE.

CONCLUSIONS

Nowadays, the first patient continues treatment with Omalizumab in order to achieve less emergency care, reduce oral corticosteroid, and reach a better quality of life.

It is being effective against the dermatitis and not showing adverse effects.

None of them developed anaphylaxis, the main adverse effect of the use of Omalizumab.